CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
11.64
-0.03 (-0.26%)
At close: Aug 1, 2025, 4:00 PM
11.64
0.00 (-0.01%)
After-hours: Aug 1, 2025, 7:37 PM EDT

Company Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.
CorMedix logo
CountryUnited States
Founded2006
IPO DateMar 25, 2010
IndustryBiotechnology
SectorHealthcare
Employees65
CEOJoseph Todisco

Contact Details

Address:
300 Connell Drive, Suite 4200
Berkeley Heights, New Jersey 07922
United States
Phone908 517 9500
Websitecormedix.com

Stock Details

Ticker SymbolCRMD
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001410098
CUSIP Number21900C308
ISIN NumberUS21900C3088
SIC Code2834

Key Executives

NamePosition
Joseph Todisco MBAChief Executive Officer and Director
Dr. Matthew T. David M.D.Executive Vice President and Chief Financial Officer
Elizabeth Masson-Hurlburt B.A.Executive Vice President and Chief Clinical Strategy and Operations Officer
Kaufman Beth Zelnick Esq.EVice President, Chief Legal, Compliance Officer and Corporate Secretary
Donna UcciSenior Vice President and Head of Global Quality
Dr. Tushar MukherjeeSenior Vice President and Head of Technical Operations
Erin MistryExecutive Vice President and Chief Commercial Officer

Latest SEC Filings

DateTypeTitle
Jun 30, 20258-KCurrent Report
Jun 30, 2025424B5Filing
Jun 26, 2025424B5Filing
Jun 25, 20258-KCurrent Report
Jun 23, 20258-KCurrent Report
May 12, 2025SCHEDULE 13G/AFiling
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 28, 2025ARSFiling
Apr 28, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material